CRISPR Therapeutics Provides Business Update and Reports First Quarter 2018 Financial Results
May 08, 2018 08:00 ET
|
CRISPR Therapeutics AG
-On track to begin CTX001 clinical study in hemoglobinopathies in 2018--On track to file IND in 2018 for CTX101, allogeneic CRISPR-based CAR-T targeted toward CD19+ malignancies--$341.8 million in...
CRISPR Therapeutics to Participate in May Investor Conferences
May 03, 2018 16:01 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based...
CRISPR Therapeutics Presents Positive Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018
April 16, 2018 16:01 ET
|
CRISPR Therapeutics AG
-Off-the-shelf CAR-T candidates against BCMA and CD70 address both hematologic malignancies and solid tumors - -New data demonstrate high editing rates, consistent expression, selective and potent...
CRISPR Therapeutics to Present Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018
April 13, 2018 08:00 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., April 13, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
CRISPR Therapeutics Announces the Appointment of Steve Caffé as Head of Regulatory Affairs
April 04, 2018 16:01 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, MA., April 04, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
CRISPR Therapeutics Announces the Retirement of Tyler Dylan-Hyde and Appointment of Shelby Walker as Head of Intellectual Property
March 26, 2018 16:01 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., March 26, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for...
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial Results
March 08, 2018 16:15 ET
|
CRISPR Therapeutics AG
- On track to begin first company-sponsored clinical trials of a CRISPR-based therapy -- Wholly-owned CRISPR-based allogeneic CAR-T programs advancing rapidly - ZUG, Switzerland and CAMBRIDGE, Mass.,...
CRISPR Therapeutics to Participate in Four Upcoming Investor Conferences
February 21, 2018 08:30 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 21, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a genome editing company focused on creating transformative medicine for...
CRISPR Therapeutics Announces Transition of Bill Lundberg, MD
February 08, 2018 16:30 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for...
CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares
January 04, 2018 19:03 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 04, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for...